JAGX: Transformative year with major funding, rare disease focus, and breakthrough clinical results
Summary
Jaguar Health says it is in a transformative year driven by a $38M non-dilutive licensing deal. The company is also sharpening its focus on rare diseases. Its crofelemer formulation has shown up to a 37% reduction in parenteral support for MVID. Regulatory filings and additional key data readouts are expected within the next 12 months.
Funding
Amount
$38.0M
Total raised
Date
June 10, 2026
Announcement date
Investors
-
Lead investors
Company
jaguar.health
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected